Before taking MEXTOVI(Binimetinib)

Important precautions include monitoring for new malignancies, cardiac function, and ocular events.

Warnings and Monitoring

Patients require comprehensive monitoring due to significant risks. This includes dermatologic evaluations for new malignancies before treatment, every 2 months during, and for 6 months after therapy. Left ventricular ejection fraction (LVEF) must be assessed before treatment, after one month, and then every 2-3 months. Regular ophthalmologic examinations are necessary for visual symptoms. Liver function tests, creatine phosphokinase (CPK), and creatinine levels should be monitored periodically. MEXTOVI can cause fetal harm, necessitating pregnancy testing and effective contraception in females of reproductive potential.